Beam Therapeutics, based in Cambridge, Mass., released early clinical data from its first trial for patients with sickle cell disease that employed a gene editing tool, known as CRISPR. All four patients showed positive results, but one died four months post-treatment, according to a Nov. 5 news release from the company.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
